logo

For the Inventor, By the Inventor

Flemington, NJ, United States of America

Steven A Middleton

This inventor holds 22 USPTO granted patents and 1 EPO patent, primarily in Kinase Inhibitors. Top assignees: Janssen Pharmaceutica Nv, Ortho-Mcneil Pharmaceutical Corp., Ortho Pharmaceutical Corporation. Active years: 2001-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven A Middleton. Retrieved from https://idiyas.com/inventor/steven-a-middleton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22

% Patents Active = 40.9

 

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 158(Granted Patents)


Company Filing History:

goldMedal19 out of 2,101 
 
Janssen Pharmaceutica Nv
 patents
silverMedal2 out of 363 
 
Ortho-Mcneil Pharmaceutical Corp.
 patents
bronzeMedal1 out of 377 
 
Ortho Pharmaceutical Corporation
 patents

Years Active: 2001-2014

Loading Chart...
Loading Chart...
Areas of Expertise:
Kinase Inhibitors
Pyrimidine Derivatives
ORL-1 Receptor Modulators
Thiazolopyridine
Spirocyclic Indolyl
Triazole Diamine
Piperazinyl Compounds
Amino Substituted Pyridinyl
22 patents (USPTO):Explore Patents
1. 8778956 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders (2014-07-15),
2. 8367825 - Substituted pyrimidinyl oxime kinase inhibitors (2013-02-05),
3. 8314234 - Bicyclic pyrimidine kinase inhibitors (2012-11-20),
4. 8299082 - 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives (2012-10-30),
5. 8153791 - Substituted pyrimidinyl oxime kinase inhibitors (2012-04-10),
6. 7888380 - 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives (2011-02-15),
7. 7855205 - Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders (2010-12-21),
8. 7659284 - Thiazolopyridine kinase inhibitors (2010-02-09),
9. 7655670 - 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators (2010-02-02),
10. 7605154 - Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors (2009-10-20),
11. 7582649 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders (2009-09-01),
12. 7541367 - 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders (2009-06-02),
13. 7517885 - Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds (2009-04-14),
14. 7482348 - Piperazinyl substituted cyclohexane-1,4-diamines (2009-01-27),
15. 7470711 - Piperidinyl substituted cyclohexane-1,4-diamines (2008-12-30),

Title: **Steven A Middleton: Innovator in Pharmaceutical Patents**

Introduction

Steven A Middleton is a prominent inventor based in Flemington, NJ, USA, with an impressive portfolio of 22 patents. His contributions to pharmaceutical innovations have significantly impacted the field of medicine, particularly in treating various disorders.

Latest Patents

Among his latest patents, Middleton has developed novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives, aimed at therapeutic applications for disorders mediated by the ORL-1 receptor. This invention is promising in targeting specific pathways related to various physiological conditions. Additionally, he has invented substituted pyrimidinyl oxime kinase inhibitors that hold potential for treating, preventing, or ameliorating chronic or acute protein kinase mediated diseases, disorders, or conditions. These advancements showcase his commitment to innovative solutions in the pharmaceutical industry.

Career Highlights

Middleton has had a distinguished career, collaborating with notable companies in the pharmaceutical sector. He has worked at Janssen Pharmaceutica and Ortho-McNeil Pharmaceutical Corporation, where he has likely contributed to groundbreaking research and product development.

Collaborations

Throughout his career, Steven A Middleton has collaborated with esteemed professionals such as Peter J Connolly and Stuart Emanuel. These partnerships have undoubtedly furthered the scope of innovation in their respective projects and contributed to successful outcomes in their shared endeavors.

Conclusion

Steven A Middleton stands out as a key figure in the realm of pharmaceutical inventions and patents. His work continues to pave the way for innovative treatments, addressing critical medical needs. As he progresses in his career, his ongoing contributions will likely lead to further advancements in the health sector.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…